Bromelain treatment reduces CD25 expression on activated CD4+ T cells in vitro
- 31 March 2009
- journal article
- Published by Elsevier BV in International Immunopharmacology
- Vol. 9 (3), 340-346
- https://doi.org/10.1016/j.intimp.2008.12.012
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Bromelain treatment decreases neutrophil migration to sites of inflammationClinical Immunology, 2008
- Oral Bromelain Attenuates Inflammation in an Ovalbumin-Induced Murine Model of AsthmaEvidence-Based Complementary and Alternative Medicine, 2008
- Dynamic changes in CD4+ CD25+ high T cell apoptosis after the diagnosis of type 1 diabetesClinical and Experimental Immunology, 2007
- Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationshipsClinical and Experimental Immunology, 2007
- Quality, efficacy and safety of complementary medicines: fashions, facts and the future. Part II: Efficacy and safetyBritish Journal of Clinical Pharmacology, 2003
- Bromelain Modulates T Cell and B Cell Immune Responses in Vitro and in VivoCellular Immunology, 2001
- Proteolytic Cleavage of CD25, the α Subunit of the Human T Cell Interleukin 2 Receptor, by Der p 1, a Major Mite Allergen with Cysteine Protease ActivityThe Journal of Experimental Medicine, 1998
- Serum levels of sCD23 and sCD25 in children with asthma and in healthy controls*Allergy, 1994
- Fibrinolytic and antithrombotic action of bromelain may eliminate thrombosis in heart patientsMedical Hypotheses, 1980
- Comparative Trial of Nutrizym in Chronic Pancreatic InsufficiencyBMJ, 1970